TY-1091

N/A

Report date: 2022/12/27 20:00:34
NME

Base Information

Drug NameTY-1091
Drug Alias NameTY-1091TY1091
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTYK Medicines Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTYK Medicines Inc
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A